Abstract: Object of the present invention is to provide various anti-podoplanin antibodies useful as a drug or reagent. The present invention provides an anti-podoplanin antibody or antigen-binding fragment thereof, each having an epitope in any of the following regions in the amino acid sequence of podoplanin represented by SEQ ID NO: 1: (i) from position 56 to position 80, (ii) from position 81 to position 103, (iii) from position 81 to position 88, and (iv) from position 25 to position 57.

Abstract: A tGal-3BP-Fc fusion protein, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, and a method of inhibiting, decreasing, reducing, suppressing or limiting metastasis of cancer cells, and immunosuppressing or modulating phagocytosis and T-cell functions by using the same are disclosed herein. The tGal-3BP-Fc fusion protein comprises: a truncated Gal-3 binding protein with domain 4, and at least an Fc fragment of an immunoglobulin G. A pharmaceutical composition comprises the tGal-3BP-Fc or Fc-tGal-3BP fusion protein, and a pharmaceutically acceptable carrier. The method comprises a step of administrating the pharmaceutical composition to a subject in a therapeutically effective amount to inhibit, decrease, reduce, suppress or limit invasiveness and metastasis of cancer cells or to treat or modulate immune reactions of inflammatory diseases in the subject.

Abstract: This disclosure provides methods for treating Hodgkin's lymphoma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody. In some embodiments, this invention relates to methods for treating Hodgkin's lymphoma in a subject comprising administering to the subject a combination of an anti-cancer agent which is an anti-Programmed Death-1 (PD-1) antibody and another anti-cancer agent such as an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody.

Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.

Abstract: Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.

Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.

Abstract: The invention relates to the production and the characterisation of new murine monoclonal antibodies that recognize the domain CTD-2 (SEQ ID NO: 1) of the cell receptor DEC-205 of dendritic cells in chickens (Gallus gallus), pigs, (Sus scrofa) and humans (Homo sapiens). The invention also relates to the capacity of the new antibodies to direct and modulate the immune response at different levels in chickens (Gallus gallus) and pigs (Sus scrofa), as well as recognising the receptor DEC-205 in dentritic cells and cell lines in humans, In addition, the invention is used to quickly produce a specific humoral immune response against Hemaglutinina H5 of the H5N2-type avian flu virus.

Abstract: The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.

Abstract: Aspects of the present disclosure relate to binding agents (e.g., antibodies and antigen binding fragments) that bind soluble fms-like tyrosine kinase 1 (sFlt1) in an isoform specific manner. In some embodiments, immunological assay methods utilizing isoform-specific antibodies or antigen binding fragments that bind sFlt1 isoforms are provided for assessing biological samples obtained from pregnant subjects, e.g., for purposes of evaluating preeclampsia status in the subject.

Abstract: The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.

Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.

Abstract: The present invention provides fusion proteins that act on the glucocorticoid-induced TNFR family-related gene (GITR) and OX40 signaling pathway. In certain aspects, the proteins of the invention are useful in modulating both regulatory T (Treg) cells and effector T (Teff) cells.

Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Abstract: Provided herein are methods of treating a solid tumor comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof, tremelimumab or an antigen-binding fragment thereof, and MEDI6383.

Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.

Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.

Abstract: The present invention is directed to the combination therapy of an anti-CD20 antibody with a Bcl-2 inhibitor and a MDM2 inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a Bcl-2 inhibitor and a MDM2 inhibitor.

Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.

Abstract: In a first aspect, the present invention relates to genetically modified T-cells having a chimeric antigen receptor (CAR) in a method for adoptive cell therapy for treating TOSO+ cancer, like B-cell leukemia/lymphoma, in a subject in need thereof. In particular, the present invention relates to a genetically engineered T-cell containing and expressing a specific chimeric antigen receptor being toxic to TOSO+ cancer cells while being less toxic or non-toxic to TOSO+ non-cancer cells, in particular, being non-toxic to normal B cells and its precursors. In a further aspect, the present invention relates to a specific chimeric antigen receptor and the nucleic acid molecule encoding the same as well as vectors and cells containing the same.

Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Abstract: The present invention concerns a conjugate comprising (i) a cell binding agent which binds to the human mucin-1 (MUC1) glycoprotein, linked to (ii) at least one cytotoxic agent, for use to treat cancer, wherein said conjugate is administered at a dose of at least 120 mg/m2.

Abstract: The present invention concerns compositions and methods of use of antibodies or antibody fragments that bind to an epitope located within the second cysteine-rich domain (Cys2, amino acid residues 1575-1725) of MUC5AC. The antibodies bind with high specificity and selectivity to pancreatic cancer and are of use for therapy, detection and/or diagnosis of pancreatic cancer. In preferred embodiments, therapeutic antibody may be conjugated to at least one therapeutic agent, such as 90Y. Both in vivo and in vitro detection of pancreatic cancer may be performed with the subject methods and compositions. Specific dosages of radiolabeled antibody and/or gemcitabine, of use in human pancreatic cancer patients, are disclosed herein.

Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.

Abstract: Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).

Abstract: The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: Methods for reducing the amount of ruminal saturation of unsaturated fatty acids and poly-unsaturated fatty acids in a ruminant by administering compositions that interfere and reduce lipolysis and/or biohydrogenation are provided. In one embodiment, the composition is antibodies that bind to immunogens involved in lipolysis and/or biohydrogenation. In another embodiment, the composition is an immunogenic composition containing immunogens involved in lipolysis and/or biohydrogenation. Method for producing the antibodies are also provided.

Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.

Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

Abstract: The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

Abstract: The present invention provides a method for the functionalization of a polymeric surface with a protein by physical adsorption. The method enables a membrane spanning protein to be used as an anchor for proteins and/or peptides for display. Also provided are polymeric substrates for protein or peptide display, and related kits and methods of use.

Abstract: Esterified cellulose ethers which have i) as ester groups aliphatic monovalent acyl groups or a combination of aliphatic monovalent acyl groups and groups of the formula ——C(O)—R—COOA wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, ii) a weight average molecular weight Mw of from 80,000 Dalton to 220,000 Dalton, iii) a Polydispersity Mw/Mn of from 1.3 to 4.0, and iv) an Mz/Mn of not more than 18.5, when the weight average molecular weight Mw, the number average molecular weight Mn and the z-average molecular weight Mz are measured by SEC-MALLS using as mobile phase a mixture produced from 40 parts by volume of acetonitrile and 60 parts by volume of aqueous buffer containing 50 mM NaH2—PO4 and 0.1 M NaNO3. are useful as enteric polymers for pharmaceutical dosage forms.

Abstract: The present invention provides a method to prepare polysaccharides from Ganoderma lucidum. The prepared polysaccharides reduce body weight and fat accumulation in laboratory animals, and can therefore be used to prevent and treat obesity.

Abstract: Disclosed are a Fuc3S4S substituted oligoglycosaminoglycan with a weight-average molecular weight (Mw) of about 4.5-9 kD, a pharmaceutical composition containing the Fuc3S4S substituted oligoglycosaminoglycan, a preparation method thereof and a use thereof in preparing medicines for preventing and/or treating thrombotic diseases.

Abstract: The present invention provides a facile method for separation (fractionation) of HA in a sample over a broad M range, including low M HA, by ion exchange (IEX) chromatography. The present invention also provides an assay method for quantifying in a sample the presence of low M HA in total HA isolated from a biological source. The method involves HA fractionation according to M by use of IEX separation, followed by HA-specific assay of HA size range fractions.

Abstract: The present invention is to provide a polymer modifying agent composition which provides a modified polymer that exhibits excellent low heat build-up when formed into a vulcanized product. The polymer modifying agent composition is a polymer modifying agent composition modifying a polymer having a carbon-carbon unsaturated bond, and containing (A) a nitrone having at least one carboxy group and (B) a fatty acid having 6 or more carbons.

Abstract: Electropolymerizable compositions are disclosed. Certain electropolymerizable compositions include one or more 1,1-disubstituted alkene compounds and one or more conductive synergists. Other certain electropolymerizable compositions include one or more 1,1-disubstituted alkene compounds and one or more acid stabilizers and one or more free radical stabilizers.

Abstract: An object of the present invention is to provide a living radical polymerization catalyst that is excellent in terms of safety and cost, and is applicable to various vinyl monomers, and to provide a method for producing a polymer using this living radical polymerization catalyst. The living radical polymerization catalyst contains at least one member selected from the group consisting of alkali metal halide compounds and alkaline earth metal halide compounds.

Abstract: The present invention relates to a A metal complex of formula 1 CyYMLjXn??(formula 1) wherein Cy is a cyclcpentadienyl-type ligand; M is a metal of group 4; L is a neutral Lewis basic ligand wherein the number of said neutral ligands “j” is in the range of 0 to the amount that satisfies the 18-electron rule: X is an anionic ligand; n is an integer denoting the number of anionic ligands X and is 1 or 2, preferably is 2; Y is a cyclic amidine-containing ligand moiety represented by formula 2 wherein the amidine-containing ligand is covalently bonded to the metal M via the imine nitrogen atom N2; S is a —CH2— unit, and t is the integer number denoting the number of S and is in the range of 1-4, more preferably in the range of 1-2, most preferably is 1; Sub1 is an aliphatic cyclic or linear substituent comprising a group 14 atom through which Sub2 is bonded to the amine nitrogen atom N1; Sub2 is an optionally substituted C2 unit in which the 2 carbon atoms may be sp2 or sp3 hybridized.

Abstract: A system and method of producing polyethylene, including: polymerizing ethylene in presence of a catalyst system in a reactor to form polyethylene, wherein the catalyst system includes a first catalyst and a second catalyst; and adjusting reactor conditions and an amount of the second catalyst fed to the reactor to control melt index (MI), density, and melt flow ratio (MFR) of the polyethylene.

Abstract: The present invention relates to processes and apparatus useful for the production of polymer powder, and in particular to processes and apparatus for the degassing of polymer powder.

Abstract: Process for functionalising an ethylene-based (co)polymer comprising the step of contacting an ethylene-based (co)polymer at a temperature in the range 100-250° C. with an azide of formula (I) wherein Y is either (Ia) or (Ib) m is 0 or 1, n is 0 or 1, n+m=1 or 2, and X is a linear or branched, aliphatic or aromatic hydrocarbon moiety with 1-12 carbon atoms, optionally containing heteroatoms.

Abstract: Disclosed are an anionic polymerization initiator, which is an organo-alkali metal compound having an anionic end including an amine group, a method of preparing a modified conjugated diene-based polymer using the same, and a rubber composition including the modified conjugated diene-based polymer prepared thereby.

Abstract: A polymerization process for stable gas phase reactor start-up when making ethylene copolymers having relatively high molecular weight distribution and melt flow ratio.

Abstract: A (meth)acrylic resin composition is obtained by a method that comprises: preparing a liquid starting material (A) comprising methyl methacrylate, an acrylic acid alkyl ester and a chain transfer agent, having a mass ratio of the acrylic acid alkyl ester to the methyl methacrylate of 0/100 to 20/80, and having a dissolved oxygen concentration of not more than 50 ppm, preparing a liquid starting material (B) comprising a radical polymerization initiator, a polymerization inhibitor and methyl methacrylate, and having been maintained at a temperature of not more than 10° C. in the presence of oxygen, continuously feeding the liquid starting material (A) and the liquid starting material (B) into a tank reactor, allowing bulk polymerization to proceed in the tank reactor at a polymerization conversion ratio of 40 to 70% by mass to give a reaction product, and continuously discharging the reaction product from the tank reactor.

Abstract: A catalyst composition for use as precursor for Ziegler-Natta catalyst system, said catalyst composition comprising a combination of magnesium moiety, titanium moiety and an internal donor containing at least one 1,2-phenylenedioate compound of structure (A). Also, the present invention provides a process for preparing the aforesaid catalyst composition. Further, the present invention provides a Ziegler-Natta catalyst system incorporating the aforesaid catalyst composition and a method for polymerizing and/or copolymerizing olefins using the Ziegler-Natta catalyst system.

Abstract: The present disclosure provides a Ziegler-Natta catalyst composition for preparing polymers of ethylene monomers having ultrahigh molecular weight, said composition comprises (i) a pro-catalyst component containing a reaction product of a magnesium containing compound and a titanium containing compound, characterized in that said pro-catalyst component comprises magnesium, titanium and chlorine in an amount ranging between 15 and 18 mole %; 20 and 23 mole %; and 60 and 64 mole %, respectively, all proportions being with respect to the total weight of the Ziegler-Natta catalyst composition; (ii) a co-catalyst component; and (iii) at least one external electron donor compound selected from the group of organosilane compounds having the general formula (I), wherein R1, R2, R3 and R4 are all the same or all are different, or some are the same, and are individually selected from the group consisting of linear or branched alkyl groups, cycloalkyl groups, aryl groups, alkoxy and aryloxy groups.

Abstract: The present invention describes a process for preparing spherical particles of a catalyst composition, the process comprising contacting an organomagnesium precursor with a transition metal compound in presence of an internal donor to obtain a reaction mixture. Thereafter heating the reaction mixture from a first pre-determined temperature to a second pre-determined temperature and then heating the reaction mixture from second pre-determined temperature to a third pre-determined temperature to obtain spherical particles of the catalyst composition. The present invention also relates to a process for preparing of a spherical catalyst system from said spherical catalyst composition and preparing a spherical polyolefins having free flowing characteristics with bulk densities (BD) of at least about 0.4 g/cc from the spherical catalyst system.

Abstract: There is provided a dispersing agent for suspension polymerization of a vinyl compound comprising a polyvinyl alcohol with a saponification degree of 65 to 90 mol % which satisfies Formulas (1) to (3). It allows for reducing the amount of coarse particles during polymerization and can thus provide a vinyl polymer with a sharp particle size distribution and higher plasticizer absorbability. 0.4?(MwUV/MwRI)?0.95??(1) 3?(MwUV/MnUV)?12??(2) 0.1?A220?0.